Subscribe to RSS
Download PDF
DOI: 10.1055/a-1692-0765
Herzrhythmusstörungen bei Frauen
Cardiac Arrhythmias in Women
Zusammenfassung
Bei Herzrhythmusstörungen zeigen sich deutliche geschlechtsspezifische Unterschiede zwischen Männern und Frauen. Diese Unterschiede reichen von der Physiologie auf zellulärer Ebene über unterschiedliche Symptome bis hin zum Zugang und Erfolg einer Therapie. In den großen randomisierten Studien sind Frauen fast immer unterrepräsentiert. Aufgrund des zunehmenden Bewusstseins über diese signifikanten Unterschiede wurde vor einigen Jahren ein Positionspapier der EHRA (European Heart Rhythm Association) veröffentlicht, auf welches im folgenden Artikel Bezug genommen wird.
Abstract
There are relevant gender differences between men and women in cardiac arrhythmias. These differences range from cellular electrophysiology and different symptoms to access and success of arrhythmia therapies. Women are often underrepresented in randomised trails. Because of the increasing awareness of these gender differences a consensus document, created by the EHRA (European Heart Rhythm Association), was published.
Bei der Diagnose und Therapie von Herzrhythmusstörungen sollten geschlechtsspezifische Unterschiede zwischen Männern und Frauen gekannt und berücksichtigt werden.
Publication History
Article published online:
09 February 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Linde C, Bongiorni MG, Birgersdotter-Green U. et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace 2018; 20: 1565-1565.ao
- 2 Rautaharju PM, Mason JW, Akiyama T. New age- and sex-specific criteria for QT prolongation based on rate correction formulas that minimize bias at the upper normal limits. Int J Cardiol 2014; 174: 535-540
- 3 Priori SG, Blomstrom-Lungqcist C, Mazzanti A. et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J 2015; 36: 2793-2867
- 4 Tadros R, Ton AT, Fiset C. et al. Sex differences in cardiac electrophysiology and clinical arrhythmias: epidemiology, therapeutics, and mechanisms. Can J Cardiol 2014; 30: 783-792
- 5 Carnlöf C, Iwarzon M, Jensen-Urstad M. et al. Women with PSVT are often misdiagnosed, referred later than men, and have more symptoms after ablation. Scand Cardiovasc J 2017; 51: 299-307
- 6 Zylla MM, Brachmann J, Lewalter T. et al. Sex-related outcome of atrial fibrillation ablation: insights from the German Ablation Registry. Heart Rhythm 2016; 13: 1837-1844
- 7 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2020; 42: 373-498
- 8 Bogle B, Ning H, Mehrotra S. et al. Lifetime risk for sudden cardiac death in the community. J Am Heart Assoc 2016; 5: e002398
- 9 Cronin E, Bogun FM, Maury P. et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace 2019; 21: 1143-1144
- 10 Brodsky M, Doria R, Allen B. et al. New-onset ventricular tachycardia during pregnancy. Am Heart J 1992; 123: 933-941
- 11 Nowak B, Misselwitz B. Do gender differences exist in pacemaker implantation? – results of an obligatory external quality control program. Europace 2010; 12: 210-215
- 12 Sticherling C, Arendacka B, Svendsen JH. et al. Sex differences in outcomes of primary prevention implantable cardioverterdefibrillator therapy: combined registry data from eleven European countries. Europace 2018; 20: 963-970
- 13 Zusterzeel R, Selzman KA, Sanders WE. et al. Cardiac resynchronization therapy in women. US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014; 174: 1340-1348